Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TLC

Taiwan Liposome (TLC) Stock Price, News & Analysis

Taiwan Liposome logo

About Taiwan Liposome Stock (NASDAQ:TLC)

Advanced Chart

Key Stats

Today's Range
$7.00
$7.09
50-Day Range
$6.76
$7.63
52-Week Range
$4.07
$7.70
Volume
12,421 shs
Average Volume
133,095 shs
Market Capitalization
$294.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taiwan Liposome and its competitors with MarketBeat's FREE daily newsletter.

TLC Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

TLC Stock Analysis - Frequently Asked Questions

Taiwan Liposome Company, Ltd. (NASDAQ:TLC) announced its quarterly earnings data on Wednesday, October, 28th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $2.28 million for the quarter, compared to analyst estimates of $0.38 million. Taiwan Liposome had a negative net margin of 299.27% and a negative trailing twelve-month return on equity of 120.45%.

Taiwan Liposome (TLC) raised $29 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 5,000,000 shares at a price of $5.80 per share. Cantor acted as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Taiwan Liposome investors own include Avino Silver & Gold Mines (ASM), Trevena (TRVN), Bionano Genomics (BNGO), Pfizer (PFE), Wells Fargo & Company (WFC), Aadi Bioscience (AADI) and BioLineRx (BLRX).

Company Calendar

Last Earnings
10/28/2020
Today
7/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TLC
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.02 million
Net Margins
-299.27%
Pretax Margin
-306.10%

Debt

Sales & Book Value

Annual Sales
$3.63 million
Price / Cash Flow
N/A
Book Value
$0.83 per share
Price / Book
8.43

Miscellaneous

Free Float
N/A
Market Cap
$294.54 million
Optionable
Not Optionable
Beta
0.99
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:TLC) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners